Announcement PDF 19 November 2024 ASX ANNOUNCEMENT 2024 Annual General Meeting – CEO’s Presentation ImpediMed Limited (ImpediMed) (ASX:IPD) provides the attached CEO’s presentation to be delivered at today’s Annual General Meeting commencing at 11.00am AEDT. Authorised for release by the Board of ImpediMed Limited. For more information, contact Leanne Ralph, Company Secretary, at leanne.ralph@bellev.com.au ImpediMed Limited 2024 Annual General Meeting Forging a new Standard of Care Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2024 ImpediMed Limited. 1 Agenda ImpediMed – FY24 Annual General Meeting Review - FY24 Financials Strategy - Focus on accelerating sales and controlling costs First application - Breast Cancer Related Lymphoedema (BCRL) New Team to execute Key Forward Indicators Value proposition Core business revenue and ARR improving Overall revenues down due to cessation of Astra Zeneca clinical trial FY24 Full-Year Results Total revenue1 SOZO Core Business2 revenue SOZO Core Business ARR Number of patient tests conducted $10.3 million $9.7 million $11.0 million 250,000 9% vs FY23 14% vs FY23 18% vs FY23 18% vs FY23 # SOZO units sold globally SOZO Core Business TCV Gross profit margin Cash balance at close of FY24 113 $9.4 million 87% $24.6 million 29% vs FY23 1% vs FY23 16% vs FY23 1.Clinical revenues (AstraZeneca) declined $1.9M from FY23 2.SOZO Core Business represents revenue from SOZO contracts in the Oncology/Lymphoedema market and excludes SOZO clinical business and legacy device/other revenues. 3 SOZO Core Business growth driven by US up 14% Global revenue by category Global revenue by geography 11.3 10.6 10.3 2.0 3.3 11.3 10.6 0.5 2.0 0.1 0.8 3.3 8.5 9.7 6.5 Core Business 0.9 1.0 FY23 Legacy/other FY24 Clinical 8.3 0.1 FY24 SOZO Core Business revenue up 14% vs. FY23. 1.1 A $ millions A $ millions 0.7 FY22 10.3 9.3 US business 90% of revenue. 6.1 FY22 North America FY23 ROW FY24 Unallocated 4 ARR is up 18% vs. FY23, and continues to show long term growth SOZO Core Business ARR1 22% 11.0 3-year CAGR2 10.1 9.3 ARR up 18% vs. FY23 ($9.3m) 8.2 7.3 6.7 A$ millions 6.1 FY21 H2 FY22 H1 FY22 H2 FY23 H1 FY23 H2 FY24 H1 FY24 H2 1.Annual Recurring Revenue (ARR) represents the amount of revenue reasonably expected to be recognised for the next 12-month period based on existing contracts, assuming installation upon sale and no churn. The amounts shown are as reported. The exchange rate used for FY24 H2 ARR calculation was 0.66699 (2023: 0.66387). 2.Compound Annual Growth Rate. 5 Patient testing grew 24% as a 3-year CAGR SOZO patient tests (000s) 24% 3-year CAGR1 18% growth vs. FY23 154 An important driver of renewals 126 92 70 40 17 8 FY18 2 32 FY19 72 62 47 FY20 FY21 New FY22 85 FY23 96 FY24 Follow up 1.Compound Annual Growth Rate (based on annual totals). 6 Immediate strategy Execute to breakeven with a focus of sales, marketing and clinical execution in BCRL 12-Month Priorities Next 12 months: Execute towards break even July 2025 Next 1-2 years: Innovate and expand GOAL 1 GOAL 2 GOAL 3 GOAL 4 GOAL 5 BCRL sales execution World-class customer experience Progress to break even Broaden Oncology Survivorship Develop new markets • Continued focus on sales execution with urgency • Manage cash burn • Support LPP implementation and patient utilisation • Progress towards break even • Oncology body composition • ROW Strategy in progress • Leg lymphoedema • Completed new product roadmap at Board for review • Execute on discussions with large IDNs on systemwide implementation • Continued progress to towards payor coverage target 85% through support of Academic Societies and KOLs • Deliver actionable insights at the point of care Ensure everything we do is underpinned by quality and integrity 7 Forging a new Standard of Care for Breast Cancer Survivorship • 4M 82% US breast cancer survivors1 Breast cancer patients are at risk of arm lymphedema due to their treatment5 310k Newly diagnosed US breast cancer patients every year1 1 in 5 Breast cancer patients will develop lymphedema2 resulting in • Isolation and depression3 • Hospitalisation risk4 • Economic burden4 1. Breast Cancer.org 2024 American Cancer Society, Inc. 2. Gillespie TC, et al. Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surg. 2018 Aug; doi: 10.21037/gs.2017.11.04. 3. Teo I, et al. Examining pain, body image, and depressive symptoms in patients with lymphedema secondary to breast cancer. Psychooncology. 2015 Nov;24(11):1377-83. Doi:10.1002/pon.3745. Epub 2015 Jan 20. PMID: 25601235. 4. Dean LT, et al. “It still affects our economic situation.” A long-term economic burden of breast cancer and lymphedema. Supp Care Canc 2017; https://doi.org/10.1007/s00520-018-4418-4. 5. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2019-2021. Atlanta: American Cancer Society; 2019. 6. Ridner SH, et al. A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. Lymphatic Research and Biology 2022. • Lymph node surgery​ • Radiation therapy​ • Taxane-based chemotherapy Preventing Breast CancerRelated Lymphedema 92% Of patients did not progress to chronic lymphedema with early detection using L-Dex and intervention through 3 years6 8 SOZO BIS: All elements in place to forge the new Standard of Care Positive Global Clinical Trial 1200 patient trial: Statistically Significant Lower Progression to Chronic Lymphoedema1 p=0.016 Absolute reduction: 11.3% Relative reduction: 59% 19.2% 7.9% $600m BCRL TAM Widespread & Increasing US Payor Coverage FDA cleared 1mil patient tests conducted • 23 US States now at Critical Mass (>80% covered lives) • 255m Covered Lives across the US • 73% US population now covered 1,000 Devices deployed globally Multiple Guidelines and Standards Support Early Detection Tape measure (23/100) BIS in updated NAPBC Standards NCCN L-Dex (7/89) PREVENT trial: n=1,200 10 US and international centers including Vanderbilt University, Mayo Clinic and MD Anderson 9 1. Published in Lymphatic Research & Biology https://www.liebertpub.com/doi/10.1089/lrb.2021.0084 SOZO BCRL: Replaces time consuming SOC with early, objective & fast detection for Breast Cancer Related Lymphoedema Current Standard of Care (SOC) Subjective or Time-Consuming Bioimpedance Spectroscopy (BIS) – FDA-cleared, Clinically Validated, Guideline Supported, Reimbursed, Early, Objective & Fast Detection L-Dex Score Examination Volume Captures Sub-Clinical, Stage 0 lymphedema that can be treated Optical Scanning Lymphography Stage 0, Subclinical Stage 1, Pitting Oedema Stage 2, Irreversible Stage 3, Elephantiasis 100% resolution 88% resolution 0% Resolution 0% Resolution 10 ImpediMed Board – New Team with Global Experience  Governance  Project delivery  Culture  Performance Non-Executive Directors Christine EmmanuelDonnelly Executive Directors Janelle Delaney Fiona Bones Andrew Grant Dr Parmjot Bains McGregor Grant Non-Executive Director Non-Executive Director Non-Executive Director CEO / Managing Director CF&OO / Executive Director Non-Executive Chair • Appointed 28 September 2023. • 30 years in IP expertise through commercialisation and strategic in-house intellectual property roles. • 4+ years in Board / healthcare governance experience. • Appointed 28 September 2023. • 30 years of project management and execution at IBM, with responsibility for the quality of delivery across Asia Pacific’s portfolio of several thousand projects. • Appointed 7 June 2024. • 20+ years global experience in finance, corporate governance and systems transformation. • Vice President of Finance, International Controller of Google • Appointed 28 • Appointed January September 2023 2024. • 20+ years working with • Medical doctor, exkey US customers and Pfizer and McKinsey, across global with 30+ years healthcare markets. global healthcare • Global Strategic experience across planning and delivery the US, Asia, Middle in healthcare globally, East and Australia. including McKinsey • 6 years Board / and ResMed. governance experience. • Appointed Director September 2023 and CFO November 2023. • Ex-Nanosonics CFO. • Experience with Board administration, governance and investor relations. Global Company Experience • Pfizer • Google • IBM • McKinsey Australian MedTech Experience • ResMed • Polynovo • Nanosonics New World Class Executive team  US healthcare market  Medtech commercialisation  Sales execution  Creating long-term value Executive Directors Executives Dr Parmjot Bains McGregor Grant Dr Steven Chen Tim Benkovic Julie Kuhlken Aaron Ogilvie Ashley Munoz Dennis Schlaht CEO / Managing Director CF&OO / Executive Director Chief Medical Officer SVP, Sales & Customer Success Senior Director, Marketing Senior Director, Product Development Director of Human Resources SVP, R&D and Technology • Appointed January 2024. • Medical doctor, exPfizer and McKinsey, with 30+ years global healthcare experience across the US, Asia, Middle East and Australia. • 6 years Board / governance experience. • Appointed Director September 2023 and CFO November 2023. • Ex-Nanosonics CFO, 13 years. • Experience with Board administration, governance and investor relations. • Appointed September 2023. • Former American Society of Breast Cancer Surgeons (ASBS) President • Surgical oncologist/ breast surgeon with 10+ years’ industry experience in drug and device product development. • Appointed April 2024. • Ex-Nanosonics 6 years, ex Head of US Sales • 30+ years' experience in medical device, SaaS, and distribution industries. • Proven history of building top performing sales teams. • Appointed October 2023. • Ex-Becton Dickenson • 25+ years’ experience in marketing and leadership. • Appointed on Exec October 2024. • Ex-Johnson and Johnson • 25+ years experience of product development leadership. • Appointed on Exec July 2024. • Broad expertise across diverse human resource functions. • Appointed June 2007. • Accomplished senior technology executive. • Broad areas of expertise including strategic planning and leadership, R&D and global technology implementations. Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2023 ImpediMed Limited. 12 Key forward looking metrics improving Q1 FY25 Pipeline Metrics and New Payor Coverage Metrics FY25 Q1 Sales Pipeline Updated Mid Q2 FY 25 585 devices Critical Mass States1 34% increase vs Q4 FY24 23 States +7 vs Q1 FY25 Q1 FY 25 NAPBC Standard Inclusion Updated Mid Q2 FY 25 SOZO at 143/570 254.7m Accredited NAPBC Institutions Covered Lives2 1 new NCCN Center SOZO at 23/33 1.Critical Mass: 80% or more of the population in a State is covered by Medicare, Medicaid or private insurance payors. 2.Covered Lives: represents the number of people nationally covered by Medicare, Medicaid or private insurance payors. 82% increase vs FY24 13 Momentum Continues Forward sales indicators improve and TCV momentum returns U.S. SOZO Units Sales Pipeline1 SOZO Core Business Quarterly TCV Sales Pipeline up 100% Record quarterly increase in TCV2 Q1 FY25 Pipeline up 34% vs. Q4 FY24 1.Total Opportunity Pipeline represents SOZO units in pipeline at end of quarter. 2. Total Contracted Value (TCV) relates to new and renewed contracts and includes any consideration for the sale of SOZO units as well as the total licence fees for the duration of the signed contracts. Typically, these contracts are for a period of three years. 14 The Value Proposition Multiple Regulatory Clearances Lymphoedema Heart Failure Renal Failure Body Comp Reimbursement 73% of US Insured Lives covered Critical mass coverage in 23 US States Lymphoedema prevention Initial TAM $600M Guideline and Standard Inclusion NCCN & NAPBC Successful Global RCT ~$110M Market Cap Platform Technology Lymphoedema Body Comp Heart Failure Renal Failure Multi-Application TAM significantly larger 1000+ Devices deployed Globally Growing Pipeline exceeds required devices to breakeven 15 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2024 ImpediMed Limited.